Latest Regulation News

Carbonxt Group Limited has initiated a $2 million Share Purchase Plan following successful capital raises, aiming to bolster its Kentucky activated carbon facility as it nears commercial production.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Aurizon Holdings reported a 3% revenue increase in its half-year FY2025 results, driven by higher coal volumes, but underlying NPAT fell 14% due to rising costs and customer mix effects. The company’s strong free cash flow supports an expanded $300 million buy-back program.

Aurizon Holdings posted a 3% revenue increase to $2.02 billion for 1HFY2025 but saw EBITDA dip 4% to $814 million, reflecting operational headwinds across key segments. The company declared a 9.2 cents per share interim dividend, signaling cautious optimism despite margin pressures.

Bendigo and Adelaide Bank has released its Basel III Pillar 3 disclosures for the year ended December 31, 2024, revealing solid capital adequacy and liquidity positions under APRA regulations. The bank maintains robust buffers amid lending growth and evolving market conditions.

Sprintex has completed commissioning of its compressor systems with Mest Water and is poised to receive a €3.8 million purchase order, marking a pivotal step in expanding its environmental technology footprint across the EU.

Entyr Limited has extended the closing date for its capital raising offers to 3 March 2025, providing investors additional time to participate in new share and option subscriptions.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Laramide Resources Ltd. has acknowledged a delayed filing of a director's interest notice due to internal illness, prompting an ASX inquiry and procedural upgrades to prevent future lapses.

Macarthur Minerals Limited reported a comprehensive loss of AUD 252,771 for Q4 2024, marking a sharp reversal from the prior year's profit. The company is navigating reduced exploration spending and strategic asset sales while facing ongoing funding challenges.

GQG Partners delivered robust full-year 2024 results, marked by a 26.9% increase in funds under management and nearly 47% growth in net revenue, underpinned by strong investment performance and strategic initiatives including Private Capital Solutions and a new Abu Dhabi office.

Cavalier Resources has completed and submitted all necessary mining approvals for the Crawford Gold Project, moving decisively toward production amid strong gold prices and ongoing funding talks.